In this phase II study evaluating T-DM1, 3.6 mg/kg once every three weeks, in 49 patients with HER2-overexpressing NSCLC, efficacy varied between HER2 IHC 2+ (Cohort 1) and IHC 3+ (Cohort 2). Here, ERBB2 is linked to non-small cell lung carcinoma.